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Abstract
Background: Most guidelines recommend a systematic screening of asymptomatic high risk patients with diabetes
for silent ischemia, but the clinical benefit of this strategy has not been demonstrated compared with the simple
control of cardiovascular risk factors. We sought to determine whether referring asymptomatic diabetic patients for
screening of silent ischemia decreases the risk of cardiovascular events compared with usual care.
Methods: DYNAMIT was a prospective, randomized, open, blinded end-point multicenter trial run between 2000
and 2005, with a 3.5 year mean follow-up in ambulatory care in 45 French hospitals. The study included 631 male
and female with diabetes aged 63.9 ± 5.1 years, with no evidence of coronary artery disease and at least 2
additional cardiovascular risk factors, receiving appropriate medical treatment. The patients were randomized
centrally to either screening for silent ischemia using a bicycle exercise test or Dipyridamole Single Photon
Emission Computed Tomography (N = 316), or follow-up without screening (N = 315). The main study end point
was time to death from all causes, non-fatal myocardial infarction, non-fatal stroke, or heart failure requiring
hospitalization or emergency service intervention. The results of a meta-analysis of DYNAMIT and DIAD, a similar
study, are also presented.
Results: The study was discontinued prematurely because of difficulties in recruitment and a lower-than expected
event rate. Follow-up was complete for 98.9% patients regarding mortality and for 97.5% regarding the main study
end point. Silent ischemia detection procedure was positive or uncertain in 68 (21.5%) patients of the screening
group. There was no significant difference between the screening and the usual care group for the main outcome
(hazard ratio = 1.00 95%CI 0.59 to 1.71). The meta-analysis of these and DIAD results gave similar results, with
narrower confidence intervals for each endpoint.
Conclusions: These results suggest that the systematic detection of silent ischemia in high-risk asymptomatic
patients with diabetes is unlikely to provide any major benefit on hard outcomes in patients whose cardiovascular
risk is controlled by an optimal medical treatment.
Trial registration: ClinicalTrials.gov: NCT00627783
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Cardiovascular diseases and particularly coronary heart
disease (CHD) are the leading causes of death in patients
with type-2 diabetes [1,2]. CHD is often asymptomatic in
these patients, and is therefore at an advanced stage when
it becomes clinically manifest [3,4]. Consequently, most
guidelines recommend a systematic screening by stress
testing of asymptomatic high risk patients with diabetes
[5,6]. Systematic screening is however costly, and has been
shown to have a rather low yield [3,7-9]. Moreover, percu-
taneous coronary intervention (PCI) has not been shown
superior to conservative therapy in non-acute CHD [10],
whereas control of cardiovascular risk factors has been
shown beneficial in diabetic patients. Consequently, the
paradigm of a more aggressive management of patients
with silent ischemia is unlikely to translate into obvious
benefits. We therefore decided to set up a multicenter,
double-blind randomized, unblinded strategy trial: DYNA-
MIT (Do You Need to Assess Myocardial Ischemia in
Type-2 diabetes) comparing systematic referral to a cardi-
ologist for the assessment of silent myocardial ischemia
with usual medical care. We also present a meta-analysis
including the results of DYNAMIT and those of DIAD, a
similar American study that was run during the same per-
iod, and published in 2009 in JAMA.
Methods
Patients
The study was approved by the Lyons investigational
review board and authorized by the French ministry of
health. Ambulatory patients who consulted a diabetes spe-
cialist in a hospital were eligible if they were 55 to 75 years
old, had type-2 diabetes and at least two of the following
cardiovascular risk factors: urinary albumin excretion > 30
mg/L or > 30 mg/24 hours, treated or untreated hyperten-
sion, treated or untreated lipid abnormality, peripheral
arterial disease, history of transient ischemic accident,
tobacco consumption and familial history of premature
cardiovascular disease. Patients were excluded if they had
a history of myocardial infarction, coronary artery disease,
or stroke, a previous positive stress test or myocardial per-
fusion imaging, or a negative stress test or myocardial per-
fusion imaging within the last three years. Patients gave a
written informed consent and provided the coordinating
centre with their full name, address and phone number,
and those of at least one relative.
Procedures
Specialists in diabetes care in 45 French hospitals rando-
mized the eligible patients to the screening or usual care
group by using a central, automated telephone procedure
stratified by investigating centre. In the usual care group,
patients were treated according to current guidelines but
were not referred to a cardiologist. Patients assigned to the
screening group were referred to a cardiologist for a sys-
tematic detection of silent ischemia by a bicycle exercise
test performed according to the French Society of Cardiol-
ogy protocol [11] after washout of cardiovascular medica-
tions likely to interfere with the test. Dipyridamole Single
Photon Emission Computed Tomography (SPECT) was
used in patients unable to perform the exercise test, with a
sub-maximal negative exercise test result or with electro-
cardiographic abnormalities impairing the interpretation
of the exercise test. SPECT results showing small defects
(uncertain results) were grouped with definitely abnormal
results (positive stress test or medium to large SPECT per-
fusion defects), due to the small number of patients. Sub-
sequent investigations (such as coronary angiography) and
treatments (such as revascularization procedures) were left
at the cardiologist’s decision.
Follow-up
Baseline cardiovascular history and risk factors, results
of the cardiac investigations, cardiovascular and anti-
diabetic medications at discharge were entered in the
case report form. Patients were followed-up after dis-
charge by the coordinating centre until the end of the
study. Patients were asked by mail every six months if
they had been hospitalized since the last contact.
Patients who did not answer were contacted by tele-
phone. The study investigators were asked at the end of
the follow-up to complete the information given by the
patients. In case of hospitalization for identified or pos-
sible cardiovascular causes, contact was established with
the hospital and with the patient’s primary care physi-
cian to document the event. Follow-up was completed
by an administrative survival inquiry. At the occasion of
the last contact, patients were asked to give a list of all
the medications that they used daily.
End points
The main end point was time to death from all causes,
non-fatal myocardial infarction (MI), non-fatal stroke, or
heart failure requiring hospitalization or emergency ser-
vice intervention. Secondary end points included the
components of the main end point, unstable angina
requiring hospitalization, coronary events (fatal or non-
fatal MI, hospitalized unstable angina, or heart failure
requiring hospitalization or emergency service interven-
tion), and coronary revascularization (angioplasty or cor-
onary artery bypass graft, including procedures decided
after the first silent ischemia detection procedure in the
screening group). All study outcomes were adjudicated
by a blinded independent event committee.
Statistical analysis
It was expected that 22% patients of the control group
would experience a main study end point over 4 years
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Page 2 of 7of follow-up (5.5% per year). Three thousand patients
were needed to obtain an 80% power to detect a 20%
relative reduction in the risk of main end point in the
screening compared with the control group.
The analysis was on intention to treat. All reported
levels of significance are two-sided, and 95% confidence
intervals (95%CI) are reported where appropriate. Time-
to-event curves were constructed according to the Kaplan-
Meier method. The study groups were compared for the
main end point and coronary events by the means of a
Cox proportional model adjusted on age, sex and presence
of albuminuria. Hazard ratios (HR) are presented with
their 95% confidence interval. Other variables were com-
pared with the use of chi-square or t-tests as appropriate.
Meta-analysis
An electronic search for reports of trials similar to
DYNAMIT was performed using the PubMed database
and the key words “("ischemia"[All Fields] OR “ische-
mia"[MeSH Terms] OR “ischemia"[All Fields]) AND
asymptomatic[All Fields] AND (("diabetes mellitus"[-
MeSH Terms] OR ("diabetes"[All Fields] AND “mellitu-
s"[All Fields]) OR “diabetes mellitus"[All Fields] OR
“diabetes"[All Fields] OR diabetic[All Fields]) AND Ran-
domized Controlled Trial[ptyp]”. The selection criteria
for including a trial in the meta-analysis were the fol-
lowing: randomized trial comparing screening with
stress test or SPECT with no screening in asymptomatic
patients with diabetes followed-up for at least one year,
and availability of cardiovascular events.
Relative risks of events were computed and combined
using the EasyMA software [12,13]. For each compari-
son, the result is given as the relative risk and its 95%
confidence interval (95%CI). Statistical significance of
the difference is given by the association p-value. Het-
erogeneity between trials and between sub-groups was
tested by the Cochrane Q-test.
Role of the funding source
The sponsors of the study had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report. The corresponding author (ML)
had full access to all the data in the study. The DYNA-
MIT group had final responsibility for the decision to
submit for publication.
Results
Study course
Recruitment began in December 2000. Mid-June 2003,
only 628 patients had been randomized by 45 centers,
and 30 main end points had been observed in 18 parti-
cipants. Consequently, considering the irremediable lack
of power the study steering committee decided to stop
recruitment on July 11, 2003. At this time, 631
randomizations had been recorded, 316 in the screening
and 315 in the control group. Follow-up continued until
July 30, 2005 (Figure 1).
Follow-up was complete for 624 patients (98.9%)
regarding mortality and for 615 (97.5%) regarding
the main study end point. Main follow-up duration was
3.5 years in both groups.
Patient characteristics
Study groups were well matched at baseline regarding
patient characteristics and cardiovascular risk factors
(Table 1). Body mass index and glycated hemoglobin
concentrations were increased as expected in this popu-
lation of patients referred to tertiary care centre. Few
patients had a history of peripheral arterial disease, tran-
sient ischemic attack or heart failure.
Stress test results and treatment at hospital discharge
In the screening group, 231 (73.1%) patients underwent
an exercise test and 98 (31.0%) SPECT. The result of
this first step of the silent ischemia detection procedure
was definitely abnormal or uncertain in 68 (21.5%)
patients. Coronary angiography was performed in 38
(12% patients). Subsequent coronary angioplasty was
performed in 9 patients, among who 7 received at least
one stent, and 3 had coronary artery bypass graft.
Medical treatments at hospital discharge following the
first study visit were similar, with only a trend toward a
more frequent use of antiplatelet drugs in the screening
group (Table 2). Reflecting the recommendations in use
a tt h et i m eo ft h es t u d yi n c e p t i o n ,s t a t i n sw e r eu s e db y
only one third of patients, but most of the patients
(70%) were treated by drugs interfering with the renin-
angiotensin system. The use of insulin in 45% patients
suggests an advanced state of metabolic impairment.
Outcomes
Twenty-eight patients experienced at least one primary
end point in the screening group and 26 in the control
631 randomized 
315 assigned to no screening 
315 had no screening 
6 lost to follow-up for  
main end point 
3 lost to follow-up for mortality 
309 included in analysis 
6 excluded (lost to follow-up) 
316 assigned to screening 
298 had screening 
18 had no screening 
10 lost to follow-up for 
main end point 
4 lost to follow-up for mortality 
306 included in analysis 
10 excluded (lost to follow-up) 
Figure 1 Study flow-chart.
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the groups (Adjusted HR = 1.00; 95%CI 0.59 to 1.71).
The only adjustment parameter that had a significant
prognostic value was increased urinary albumin excre-
tion (HR = 2.58; 95%CI 1.45 to 4.58). There was a trend
toward a lower number of MIs and a higher number of
strokes in the screening compared with the control
group (Table 3), but the absolute numbers of events
were small. Coronary events occurred in 13 and 15
patients in the screening and control groups respectively
(HR = 0.77; 95%CI 0.37 to 1.63). Coronary revasculari-
zation was performed in 18 and 21 patients in the
screening and control groups respectively (p = 0.61).
Overall the absolute risk of major cardiovascular event
was 2.4% per year.
Safety
No serious adverse event was reported during the initial
hospitalization of patients. Adverse events that occurred
during follow-up were not recorded.
Meta-analysis
Our PubMed search yielded only one eligible trial, the
D e t e c t i o no fI s c h e m i ai nA symptomatic Diabetics
(DIAD) [14]. This study was launched in 2000 and
included 1123 50-75 years old patients with diabetes,
561 of which were allocated to SPECT and 562 to fol-
low-up only. Any evidence of coronary heart disease,
and stress test or coronary angiography within the prior
3 years were exclusion criteria. The prevalence of
SPECT abnormalities (including small defects) was the
same as that of silent ischemia in our study (22%)
whether the patients had or not at least two additional
cardiovascular risk factors. With a longer follow-up
duration of 4.8 years, the yearly risks of death from all
Table 1 Baseline patient characteristics by randomization
group
Parameter Usual care Screening
Age (years) 63.7 ± 6.4 64.1 ± 6.4
Males (%) 53.7 55.4
BMI (kg/m²) 30.8 ± 5.3 30.4 ± 4.7
HbA1C (%) 8.7 ± 2.0 8.6 ± 2.2
Lipid abnormality (%) 81.6 80.4
History of TIA (%) 3.8 5.4
History of heart failure (%) 0 1.0
History of peripheral arterial disease (%) 14.3 13.9
Familial history of cardiovascular disease (%) 21.0 21.8
Tobacco consumption (%) 14.6 17.4
Hypertension (%) 88.3 89.2
Increased urinary albumin excretion (%) 40.3 44.0
BMI = body mass index; TIA = transient ischemic attack. Quantitative values
are given as means and (SD).
Table 2 Treatments at hospital discharge (% patients) by
randomization group
Medication Usual care Screening
Metformin 67.9 61.7
Sulfonylurea 52.4 47.5
Other oral antidiabetic drugs 23.5 25.6
Insulin 44.4 45.6
Statin 35.9 33.5
Fibrate 24.1 25.3
Aspirin 24.1 29.1
Other antiplatelet drug 5.4 7.6
Diuretic 37.8 42.7
Beta-blocker 16.5 23.4
ACE-inhibitor 53.0 50.6
Angiotensin receptor blocker 15.9 19.0
Calcium channel blocker 27.6 25.6
Figure 2 Survival curve for the main composite end-point
(time to death from all causes, non-fatal myocardial infarction,
non-fatal stroke, or heart failure requiring hospitalization or
emergency service intervention).
Table 3 Adjudicated events (number of patients with at
least one event during follow-up) by randomization
group
Usual care Screening
Main end point * 26 28
Myocardial infarction 8 4
Stroke 4 9
Hospitalized cardiac failure 4 5
All cause deaths 13 15
Coronary events † 15 13
Revascularization 21 18
* death from all causes, non-fatal myocardial infarction, non-fatal stroke, or
heart failure requiring hospitalization or emergency service intervention. †fatal
or non-fatal MI, hospitalized unstable angina, or heart failure requiring
hospitalization or emergency service intervention.
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(0.59%) were much smaller than in DYNAMIT (respec-
tively 1.27% and 0.95%).
The results of the meta-analysis are shown in Figure 3.
Unfortunately, we were unable to obtain the DIAD
results corresponding to our main end point from the
DIAD investigators. The main DIAD end point (cardiac
death or non-fatal MI) could however be obtained for
DYNAMIT, allowing its inclusion in the meta-analysis.
No heterogeneity was detected between the trials (p >
0.7 for all end points). No significant favorable effect of
screening was detected, although there was a favorable
trend for non-fatal MI (RR = 0.61 [0.29 to 1.29], p =
0.20), and an adverse trend for stroke (RR = 2.11 [0.96
to 4.64], p = 0.06).
Conclusions
Compared with no cardiologic investigation, the sys-
tematic detection of silent ischemia in asymptomatic
patients with type-2 diabetes at a high cardiovascular
risk did not result in a lower incidence of death, non-
fatal MI, non-fatal stroke, or heart failure requiring
hospitalization over 3.5 years of follow-up in this rando-
mized strategy trial. No significant difference either was
detected regarding the incidence of coronary events and
revascularization. Due to premature study interruption
following difficulties in patient recruitment, the trial had
an insufficient power and does not allow ruling out a
41% decrease, as well as a 71% increase in the risk of
primary end point in the screening group. However, a
meta-analysis of DYNAMIT and DIAD, a very similar,
slightly more powerful study, gave the same results, nar-
rowing confidence intervals for all end points. It is
unfortunate we could not obtain the DIAD results for
our composite end point from the trial investigators.
Considering all the components of this end point in the
DIAD study, it is evident, however, that the results
would have been very close to those of DYNAMIT.
Owing to the number of secondary end points tested,
and the fact that strokes were not related to study pro-
cedures, the adverse trend regarding stroke is likely to
be a chance finding.
DYNAMIT has several weaknesses that cannot be
ignored. Firstly, it was an open trial, like all strategy
trials, and so was DIAD. A selection bias due to the
absence of blinding is however unlikely because the cen-
tral randomization procedure recorded the patient iden-
tity before giving the randomization group. Additionally
the investigator therapeutic choices might have been
influenced by the group to which the patient belonged.
In fact, this bias is unlikely since treatments prescribed
to the patients at hospital discharge were very similar in
both groups. The insufficient statistical power is a major
drawback of DYNAMIT and DIAD. Among the multiple
reasons that led to recruitment difficulties and early ter-
mination of our trial, the most important was the exis-
tence of professional recommendations to detect silent
ischemia in patients eligible to the trial, which limited
the number of investigators and resulted in a high pro-
portion of diabetic patients already screened by an exer-
cise test in the three preceding years. This may also
explain why the recruited patients had a lower-than-
expected risk of primary events despite a conservative
inclusion of patients with 2 additional risk factors.
Moreover DYNAMIT was an academic trial and recruit-
ment was hampered by competition with industry-
sponsored trials targeting the same population. It is of
note that DIAD, despite its bigger sample size and
longer follow-up, was only slightly more powerful than
DYNAMIT because it included patients at a much
lower risk of events. In fact, only 60% of the DIAD
patients had at least 2 cardiovascular risk factors com-
pared with 100% in DYNAMIT.
One of the salient features of DYNAMIT was the cen-
tralized independent follow-up. Only a small number of
patients were lost to follow-up over 3.5 years although
the protocol did not require patients to come back to
refill a prescription or have a test done. Contact with
patients was excellent, and those who were lost to fol-
low-up had moved without notifying the investigator,
their primary physician, and even their relatives. These
patients would have been missed by a classical follow-up
as well.
The DYNAMIT and DIAD studies bring thoughtful
information. They are to our knowledge the only rando-
mized trials to compare systematic silent ischemia
detection with follow-up only in asymptomatic diabetic
patients with additional cardiovascular risk factors.
Although both studies lacked power, they did not sug-
gest that systematic screening for silent myocardial
ischemia in this type of patients allowed making better
therapeutic options than watchful follow-up.
0.96 [0.57; 1.64]  0.89  0.70 
2.11 [0.96; 4.64]  0.06  0.89 
1.09 [0.48; 2.46]  0.83  0.80 
0.61 [0.29; 1.29]  0.2  0.66 
1.18 [0.72; 1.93]  0.52  0.93 
0.2 1.0 3.0 5.0
All-cause death 
Non-fatal MI 
Heart failure 
Stroke
Card. death / n-f MI 
RR [95% CI]
p
(assoc)
p
(het)
Figure 3 Meta-analysis of the DYNAMIT and DIAD study
results. Relative risks (RR) and 95% confidence intervals (95% CI),
with usual care as the reference group. Main outcome of the DIAD
study (cardiac death or non-fatal myocardial infarction (Card. Death/
n-f MI) and other outcomes. P(assoc): association p-value. P(het):
heterogeneity p-value.
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AGE and BARI 2D trial results [15,16]. In Courage, 2287
patients with objective evidence of myocardial ischemia
were randomized to PCI and optimal medical therapy ver-
sus medical therapy alone. After 4.6 years, there was no
difference between the study groups in the composite of
death or MI, and death, MI or stroke. Similar results were
obtained in the 766 patients with diabetes (hazard ratio =
0.99; 95%CI 0.73 to 1.32). In BARI 2D, 2368 patients with
both type 2 diabetes and heart disease were randomized to
either prompt revascularization with intensive medical
therapy or intensive medical therapy alone. At 5 years,
there was no difference between the groups for survival
(revascularization 88.3%, medical therapy 87.8%, p = 0.97),
nor for MI or stroke-free survival (77.2% vs 75.4%, p =
0.70). Thus, systematic revascularization does not appear
to improve the prognosis of type-2 diabetics with coronary
heart disease when metabolic and cardiovascular risk fac-
tors are controlled appropriately. Consequently, increasing
the access of asymptomatic patients with diabetes to PCI
through the detection of silent ischemia cannot be
expected to improve prognosis.
Systematic screening of asymptomatic patients with
diabetes is costly, and may affect negatively the quality
of life of one in five patients by putting them into the
heart disease population, with no expectable benefit. On
the other hand, the majority of patients, who will test
negative, may be falsely reassured, and less likely to
adhere to efficient medical treatment and healthy life-
style. Diabetic asymptomatic patients who may benefit
from screening are still to be defined.
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